However, a potent and durable anti-tumor immunoresponse depends heavily on the interplay between CD4+ and CD8+ T cells, and the co-presence of specific CD4+ and CD8+ T cells in the tumor tissue is regarded as a good prognostic factor 22, 23, indicating that a concurrent elicitation of the MHC class I and II immunity is needed 24-26. The gene discussed is CD4; the disease is neoplasm.